470 related articles for article (PubMed ID: 19595724)
21. Exploring RNA interference as a therapeutic strategy for renal disease.
Takabatake Y; Isaka Y; Mizui M; Kawachi H; Shimizu F; Ito T; Hori M; Imai E
Gene Ther; 2005 Jun; 12(12):965-73. PubMed ID: 15729369
[TBL] [Abstract][Full Text] [Related]
22. Small interfering RNA (siRNA) delivery into murine bone marrow-derived dendritic cells by electroporation.
Jantsch J; Turza N; Volke M; Eckardt KU; Hensel M; Steinkasserer A; Willam C; Prechtel AT
J Immunol Methods; 2008 Aug; 337(1):71-7. PubMed ID: 18514219
[TBL] [Abstract][Full Text] [Related]
23. An intracellular delivery method for siRNA by an arginine-rich peptide.
Wang YH; Hou YW; Lee HJ
J Biochem Biophys Methods; 2007 Jun; 70(4):579-86. PubMed ID: 17320189
[TBL] [Abstract][Full Text] [Related]
24. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.
Tagami T; Suzuki T; Matsunaga M; Nakamura K; Moriyoshi N; Ishida T; Kiwada H
Int J Pharm; 2012 Jan; 422(1-2):280-9. PubMed ID: 22101286
[TBL] [Abstract][Full Text] [Related]
25. Delivery of DNA and siRNA by novel gemini-like amphiphilic peptides.
Damen M; Aarbiou J; van Dongen SF; Buijs-Offerman RM; Spijkers PP; van den Heuvel M; Kvashnina K; Nolte RJ; Scholte BJ; Feiters MC
J Control Release; 2010 Jul; 145(1):33-9. PubMed ID: 20381554
[TBL] [Abstract][Full Text] [Related]
26. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs.
de Jonge J; Holtrop M; Wilschut J; Huckriede A
Gene Ther; 2006 Mar; 13(5):400-11. PubMed ID: 16267567
[TBL] [Abstract][Full Text] [Related]
27. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents.
Perez AP; Romero EL; Morilla MJ
Int J Pharm; 2009 Oct; 380(1-2):189-200. PubMed ID: 19577619
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes.
Altin JG; White FA; Easton CJ
Biochim Biophys Acta; 2001 Aug; 1513(2):131-48. PubMed ID: 11470085
[TBL] [Abstract][Full Text] [Related]
29. Efficient and safe delivery of siRNA using anionic lipids: Formulation optimization studies.
Kapoor M; Burgess DJ
Int J Pharm; 2012 Aug; 432(1-2):80-90. PubMed ID: 22575754
[TBL] [Abstract][Full Text] [Related]
30. siRNA stabilization prolongs gene knockdown in primary T lymphocytes.
Mantei A; Rutz S; Janke M; Kirchhoff D; Jung U; Patzel V; Vogel U; Rudel T; Andreou I; Weber M; Scheffold A
Eur J Immunol; 2008 Sep; 38(9):2616-25. PubMed ID: 18792414
[TBL] [Abstract][Full Text] [Related]
31. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
[TBL] [Abstract][Full Text] [Related]
32. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes.
Schlegel A; Largeau C; Bigey P; Bessodes M; Lebozec K; Scherman D; Escriou V
J Control Release; 2011 Jun; 152(3):393-401. PubMed ID: 21497175
[TBL] [Abstract][Full Text] [Related]
33. Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study.
Khatri N; Baradia D; Vhora I; Rathi M; Misra A
AAPS PharmSciTech; 2014 Dec; 15(6):1630-43. PubMed ID: 25145330
[TBL] [Abstract][Full Text] [Related]
34. Rapid delivery of small interfering RNA by biosurfactant MEL-A-containing liposomes.
Inoh Y; Furuno T; Hirashima N; Kitamoto D; Nakanishi M
Biochem Biophys Res Commun; 2011 Oct; 414(3):635-40. PubMed ID: 22001930
[TBL] [Abstract][Full Text] [Related]
35. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery.
Höbel S; Prinz R; Malek A; Urban-Klein B; Sitterberg J; Bakowsky U; Czubayko F; Aigner A
Eur J Pharm Biopharm; 2008 Sep; 70(1):29-41. PubMed ID: 18499413
[TBL] [Abstract][Full Text] [Related]
36. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
37. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate.
Kim SH; Mok H; Jeong JH; Kim SW; Park TG
Bioconjug Chem; 2006; 17(1):241-4. PubMed ID: 16417275
[TBL] [Abstract][Full Text] [Related]
39. Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha.
Bouclier C; Moine L; Hillaireau H; Marsaud V; Connault E; Opolon P; Couvreur P; Fattal E; Renoir JM
Biomacromolecules; 2008 Oct; 9(10):2881-90. PubMed ID: 18788777
[TBL] [Abstract][Full Text] [Related]
40. siRNA delivery by magnetofection.
Mykhaylyk O; Zelphati O; Rosenecker J; Plank C
Curr Opin Mol Ther; 2008 Oct; 10(5):493-505. PubMed ID: 18830925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
